We have challenged the currently accepted paradigm that T2D is only a metabolic disorder and that depression is purely a mental disorder; we showed that they are, at least partially and/or in a subgroup of patients, associated with CRHR1 variants, likely conferring predisposition to hyperactivity of the neuro-endocrine glucocorticosteroid pathway. This evidence concerns the gene CRHR1 and depressive symptom measurement.